MYT1L Syndrome: a Rare Paediatric Genetic Syndrome Responsible for a Neurodevelopmental Disorder

Recruiting N/A Interventional Study
MYT1L Syndrome
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
6 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
50 (estimated)
Sponsor
University Hospital, Rouen · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
MYT1L syndrome is a rare genetic syndrome, recently described in 2011, with paediatric onset, responsible for a neurodevelopmental disorder combining psychomotor retardation, learning difficulties and/or intellectual development disorders, epilepsy, overweight and eating disorders. The Rouen genetics department is currently positioned as a clinical expert in this disease. The study published in 2…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: MYT1L Group Patients * Minimum age for inclusion: 6 years * Maximum age for inclusion: no upper age limit * Language: French * Consent of parents or legal guardian * Social security coverage required Prosody Group Patients * Unaided visual or hearing impairment making assessm…
Contacts

David DM MALLET, Director

02 32 88 82 65

David.Mallet@chu-rouen.fr

CONTACT

Vincent VF FERRANTI, ARC

02 32 88 82 65

Vincent.Ferranti@chu-rouen.fr

CONTACT